To include your compound in the COVID-19 Resource Center, submit it here.

Cubist reports Phase II data

Cubist Pharmaceuticals Inc. (NASDAQ:CBST) reported data from Phase II trials of CXA-201 to treat complicated intra-abdominal infections (cIAIs) and CB-183,315 to treat Clostridium difficile

Read the full 242 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE